{"analyses":[{"ciNumSides":"TWO_SIDED","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.02","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.688","paramType":"Mean Difference (Net)","paramValue":"-0.01","statisticalMethod":"Mixed Models Analysis"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.01","value":"0.01"},{"groupId":"OG001","spread":"0.01","value":"0.01"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"328"},{"groupId":"OG001","value":"165"}],"units":"Participants"}],"description":"The EuroQol-5D (version 5L) is a brief self-administered, validated instrument consisting of 2 parts.The first part consists of 5 descriptors of current health state (mobility, self care, usual activities, pain/discomfort, and anxiety/ depression); a participant is asked to rate each state on a five level scale (no problem, slight problem, moderate problem, severe problem and extreme problem) with higher levels indicating greater severity/ impairment. Published weights are available that allow for the creation of a single summary score called the EQ-5D index that ranges from 0 to 1, with low scores representing a higher level of dysfunction and 1 as perfect health. Minimally important differences in the EQ-5D index score are 0.06 or greater in cancer patients. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, Visit, Treatment\\*Visit and Baseline.","dispersionType":"Standard Error","groups":[{"description":"150 mg Abemaciclib orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).","id":"OG000","title":"Abemaciclib + NSAI"},{"description":"Placebo orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).","id":"OG001","title":"Placebo + NSAI"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"All randomized participants.","reportingStatus":"POSTED","timeFrame":"Baseline, End of Study (Up to 32 Months)","title":"Change From Baseline to End of Study in Health Status on the EuroQuol 5-Dimension 5 Level (EuroQol-5D 5L) Index Value","type":"SECONDARY","unitOfMeasure":"units on a scale"}